In 2013 Eisai expanded its geographical business by establishing a Russia sales and Marketing operation. The Moscow based office is supported and overseen by the EMEA headquarters out of the Hatfield facility in the UK.
Eisai’s office in Russia are dedicated to establishing Eisai as a key presence in the Russian pharmaceutical sector with its Oncology and Epilepsy brands.
Eisai is a world leader in innovation. Its R&D programme includes clinical trials taking place across Russia in both Neurology and Oncology. The Russian office furthers Eisai’s vision to secure patient access to innovative and novel treatments not previously available to them.
Eisai Russia has applied for regulatory approval for Fycompa® (perampanel) for the treatment of partial epilepsy and Inovelon® (rufinamide) for the treatment of Lennox-Gastaut Syndrome (LGS).